Navigation Links
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Date:7/22/2009

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration.( ) In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.( )

"Pediatric patients may require ADHD symptom improvement both at school and after school,"( )said Sharon Wigal, PhD, lead investigator of the study, clinical professor of pediatrics and director of clinical trials in the Child Development Center at the University of California, Irvine. "These published data are the first to have shown duration of effect of an oral ADHD stimulant in children aged 6 to 12 at 13 hours after administration. Physicians and caregivers who are seeking a long-acting medication that provides ADHD symptom improvement from morning through homework and family time may want to consider this Vyvanse study data."( )

On May 22, 2009, the US Food and Drug Administration (FDA) approved a change to the prescribing information for Vyvanse to include supplemental data that demonstrated significant ADHD symptom improvement in children aged 6 to 12 from the first time point measured (1.5 hours) up to 13 hours postdose. Vyvanse is now the first and only oral ADHD stimulan
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Moderna Therapeutics, the pioneering company developing messenger RNA ... in vivo production of therapeutic proteins, announced ... join Moderna in early July as its first Chief ... leader in the design and implementation of information systems ... translation, clinical operations and commercial preparedness. John has also ...
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... 21, 2013  On May 9, 2013, FTI ... global business advisory firm dedicated to helping organizations ... announced that it has combined the healthcare and ... within the Corporate Finance/Restructuring segment with those in ... a single integrated practice whose financial results and ...
(Date:5/21/2013)... , May 21, 2013  The Lindsley F. Kimball Research ... it is a Grand Challenges Explorations winner, an ... .  Dr. Sara Lustigman , Head of ... health and development research project, titled Innovative 3-D ... worms are needed to screen drugs to help eliminate onchocerciasis ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3
... COSTA MESA, Calif., March 26 Oxygen Biotherapeutics, Inc. ... has added clinical trial sites in Israel for the ... traumatic brain injury (TBI). Oxycyte is the company,s perfluorocarbon ... addition to those previously planned for Switzerland."Israeli physicians are ...
... Renewable fuels provider New Generation Biofuels Holdings, ... today announced that it is has signed a sales ... Maryland to supply up to 370,00 gallons of renewable ... and environmentally aware company like Catoctin Mountain Growers with ...
... March 26 Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... will present at the Future Leaders in the Biotech ... Center in New York City on Thursday, April 2, ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel 2New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel 2New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel 3Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009 2Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009 3
(Date:5/22/2013)... insects and wild plants have slowed in recent years, ... the University of Leeds and the Naturalis Biodiversity Centre ... in the diversity of species in Britain, Belgium and ... the picture brightened markedly after 1990, with a slowdown ... and wild plants. , Professor Bill Kunin, ...
(Date:5/22/2013)... 22, 2013. Plastic additives known as phthalates (pronounced ... They turn up in flooring, plastic cups, beach ... Centers for Disease Control and Preventionthe bodies of ... come under increasing scrutiny. A growing collection of ... leech from packaging and mix with food) may ...
(Date:5/21/2013)... a long time that some creatures evolve more quickly ... plants. But it may be that height plays a ... the U. S. National Evolutionary Synthesis Center. , ... the journal Nature Communications , Lanfear and colleagues ... from a database of global patterns in plant height ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Small but speedy: Short plants live in the evolutionary fast lane 2
... between Plant Physiology and The Arabidopsis Information Resource (TAIR) ... genetic and molecular data on Arabidopsis published in the ... collaborationthe first of its kind-- provides authors with the ... and gene information to the TAIR database at the ...
... are natural filters that help remove and transform pollutants ... human activities. Scientists know this as a result of ... dirty, at least very wet -- monitoring streams nationwide. ... reduces the potential for eutrophication the excessive growth ...
... 12, 2008 Tiny organisms play a powerful role in ... activity, in streams, according to a study by a team ... In the first phase of the study, which involved ... small amounts of an uncommon non-radioactive isotope of nitrogen to ...
Cached Biology News:Plant Physiology and TAIR partnership will provide genetic information to public database 2Plant Physiology and TAIR partnership will provide genetic information to public database 3Streams natural filters, if not overloaded 2ORNL study finds rivers play part in removing nitrogen 2
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: